Affinity Asset Advisors bought 61,500 shares of Apogee Therapeutics for $3.87 million, increasing their stake to 1,234,926 shares valued at $93.21 million. Apogee’s stock price rose to $67.78, up 86.9% YoY, with 75.14 alpha points against the S&P 500. The company develops biologic therapies for inflammatory diseases like atopic dermatitis and COPD.

Apogee Therapeutics focuses on monoclonal antibodies for chronic diseases, aiming for regulatory approval. The company targets healthcare providers and clinics treating inflammatory conditions. Shares of Apogee were priced at $67.78 on Feb 13, 2026, with a market cap of $4 billion and net income of ($253.67 million).

Affinity Asset Advisors’ top holdings include Apogee, Insmed, Abivax, Ventyx, and Xenon, with Apogee being the largest at $93.21 million. The firm’s biotech portfolio concentrates on clinical-stage names, showing confidence in Apogee’s monoclonal antibody pipeline. Clinical data, regulatory milestones, and capital discipline drive long-term outcomes.

Motley Fool’s Stock Advisor team did not include Apogee Therapeutics in their top 10 stock picks. Their total average return is 884%, outperforming the S&P 500. Investors can access the latest list through Stock Advisor for potential high returns. Apogee’s stock has surged 87% in one year as Affinity increased its stake to $93 million, showing strong momentum in the biotech sector.

Read more at Yahoo Finance: Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million